MiR149 Rs71428439 Polymorphism and Risk of Clear Cell Renal Cell Carcinoma: a Case-control Study

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Sep 13

PMID 25213695

Citations 8

Authors

Zhigang Wang

Meng Wei

Yi Ren

Hua Liu

Meng Wang

Kehui Shi

Hongli Jiang

Affiliations

Soon will be listed here.

Abstract

Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell cancer and accounts for 70 % of renal cell cancer. CCRCC remains an enigmatic tumor type, as the molecular genetic mechanisms are still unclear. MicroRNA (miR) 149 functions as a tumor suppressor and plays an important role in the carcinogenesis of renal cells. In this study, we enrolled 1,000 CCRCC patients and 1,000 cancer-free controls to evaluate the association of miR149 rs71428439 with the risk of CCRCC by a case-control study to determine the effects on CCRCC risk. miR149 rs71428439 was significantly associated with increased CCRCC risk (odds ratio (OR) for trend = 1.53, P for trend = 4.04 × 10(-11)), with ORs (95 % confidence intervals (CIs)) of 1.42 (1.17-1.72) associated with AG genotype and 2.27 (1.76-2.94) associated with GG genotype, compared with subjects with AA genotype. The expression levels of miR149 in cancer tissues were significantly lower than those in adjacent normal tissues (P = 0.005), and per G allele has significantly lower miR149 levels in both tumor tissues and adjacent normal tissues. Our data suggest that the GG genotypes of miR149 rs71428439 predispose their carriers to CCRCC, and miR149 rs71428439 may be a new biomarker for predicting the risk of CCRCC.

Citing Articles

Let-7i-5p enhances cell proliferation, migration and invasion of ccRCC by targeting HABP4.

Liu Y, Hu X, Hu L, Xu C, Liang X BMC Urol. 2021; 21(1):49.

PMID: 33775245 PMC: 8005230. DOI: 10.1186/s12894-021-00820-9.

A New Method for Biostatistical Pattern Recognition with Topological Properties of Visibility Graphs in 3D Space.

Babic M, Marina N, Mrvar A, Dookhitram K, Cali M J Healthc Eng. 2019; 2019:4373760.

PMID: 31281616 PMC: 6594254. DOI: 10.1155/2019/4373760.

Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response.

Fang C, Li X, Chen Y, Wu N, Yin J, Zhang W J Thorac Dis. 2018; 10(6):3329-3340.

PMID: 30069329 PMC: 6051820. DOI: 10.21037/jtd.2018.05.145.

Regulation and functions of MicroRNA-149 in human cancers.

Zhi Y, Zhou H, Mubalake A, Chen Y, Zhang B, Zhang K Cell Prolif. 2018; 51(5):e12465.

PMID: 29999552 PMC: 6528861. DOI: 10.1111/cpr.12465.

miR-149 in Human Cancer: A Systemic Review.

He Y, Yu D, Zhu L, Zhong S, Zhao J, Tang J J Cancer. 2018; 9(2):375-388.

PMID: 29344284 PMC: 5771345. DOI: 10.7150/jca.21044.

References

Loron M, Grange S, Guerrot D, Di Fiore F, Freguin C, Hanoy M . Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. J Clin Oncol. 2014; 33(8):e45-7. DOI: 10.1200/JCO.2013.49.9277. View

Zhao A, Li G, Peoch M, Genin C, Gigante M . Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2012; 94(1):115-20. DOI: 10.1016/j.yexmp.2012.10.005. View

Ruvkun G . Clarifications on miRNA and cancer. Science. 2006; 311(5757):36-7. DOI: 10.1126/science.311.5757.36d. View

Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X . MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2014; 21(2):83-91. DOI: 10.3727/096504013X13775486749218. View

Shimono Y, Zabala M, Cho R, Lobo N, Dalerba P, Qian D . Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009; 138(3):592-603. PMC: 2731699. DOI: 10.1016/j.cell.2009.07.011. View

Wang F, Ma Y, Zhang P, Shen T, Shi C, Yang Y . SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol. 2012; 229(1):12-24. DOI: 10.1002/path.4078. View

Sozzi G, Boeri M, Rossi M, Verri C, Suatoni P, Bravi F . Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014; 32(8):768-73. PMC: 4876348. DOI: 10.1200/JCO.2013.50.4357. View

Brugarolas J . Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014; 32(18):1968-76. PMC: 4050206. DOI: 10.1200/JCO.2012.45.2003. View

Song T, Zhang X, Wang C, Wu Y, Cai W, Gao J . MiR-138 suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in clear cell renal cell carcinoma 786-O cells. Asian Pac J Cancer Prev. 2011; 12(5):1307-11. View

10.

Chae Y, Kim J, Lee S, Kang B, Lee Y, Park J . A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013; 33(8):3233-9. View

11.

Zadran S, Remacle F, Levine R . miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci U S A. 2013; 110(47):19160-5. PMC: 3839764. DOI: 10.1073/pnas.1316991110. View

12.

Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R . Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013; 108(1):131-8. PMC: 3553529. DOI: 10.1038/bjc.2012.537. View

13.

Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo F . Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell. 2014; 156(5):893-906. PMC: 3982296. DOI: 10.1016/j.cell.2013.12.043. View

14.

Huang Q, Ma X, Zhang X, Liu S, Ai Q, Shi T . Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4. PLoS One. 2013; 8(6):e67294. PMC: 3694928. DOI: 10.1371/journal.pone.0067294. View

15.

Lin R, Lin Y, Yu A . miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog. 2010; 49(8):719-27. DOI: 10.1002/mc.20647. View

16.

Wang Y, Zhang X, Li H, Yu J, Ren X . The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013; 92(3):123-8. DOI: 10.1016/j.ejcb.2012.11.004. View

17.

De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P . Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014; 15(4):e170-7. DOI: 10.1016/S1470-2045(13)70569-2. View

18.

Omrani M, Hashemi M, Eskandari-Nasab E, Hasani S, Mashhadi M, Arbabi F . hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomark Med. 2014; 8(2):259-67. DOI: 10.2217/bmm.13.118. View

19.

Heneghan H, Miller N, Kerin M . Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol. 2010; 28(29):e573-4. DOI: 10.1200/JCO.2010.29.8901. View

20.

Hildebrandt M, Gu J, Lin J, Ye Y, Tan W, Tamboli P . Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010; 29(42):5724-8. DOI: 10.1038/onc.2010.305. View